IQV · NYQ · Healthcare
IQVIA Holdings Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 128.47
Market price
USD 266.42
Implied upside
-51.8%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 17.0bn | USD 17.7bn | USD 18.5bn | USD 19.2bn | USD 20.0bn | +4.2% |
| EBIT | USD 2.3bn | USD 2.4bn | USD 2.5bn | USD 2.7bn | USD 2.8bn | +4.2% |
| NOPAT | USD 1.9bn | USD 2.0bn | USD 2.1bn | USD 2.2bn | USD 2.3bn | +4.2% |
| Add depreciation & amortisation | USD 1.3bn | USD 1.3bn | USD 1.4bn | USD 1.4bn | USD 1.5bn | +4.2% |
| Less capital expenditure | USD -706.0m | USD -735.7m | USD -766.7m | USD -799.1m | USD -832.7m | +4.2% |
| Less increase in working capital | USD 95.0m | USD 99.0m | USD 103.1m | USD 107.5m | USD 112.0m | -4.2% |
| Free cashflow to firm | USD 2.6bn | USD 2.7bn | USD 2.8bn | USD 2.9bn | USD 3.1bn | +4.2% |
| Discount factor | 0.9565 | 0.8750 | 0.8005 | 0.7323 | 0.6700 | - |
| Present value | USD 2.5bn | USD 2.4bn | USD 2.3bn | USD 2.2bn | USD 2.1bn | -4.7% |
| Present Value Of The Forecast | USD 11.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.125 | Reported 1.186, pulled toward 1.0 (Blume) |
| Cost of equity | 11.18% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 43.9bn | 73.3% of capital |
| Total debt | USD 15.9bn | 26.7% of capital, book value as a proxy |
| Tax rate | 16.9% | Effective, capped at statutory |
| WACC | 9.31% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
69% of EV
- Forecast FCFF, final year
- USD 3.1bn
- Capex at depreciation, working capital in reinvestment
- USD 3.4bn
- Less reinvestment at g/ROIC (26.9% of NOPAT)
- USD -902.6m
- Capitalised
- USD 2.5bn
- ROIC (WACC floor)
- 9.3%
- Terminal value, undiscounted
- USD 37.0bn
- Terminal value, discounted
- USD 24.8bn
- Enterprise value
- USD 36.1bn
- Less net debt
- USD 13.8bn
- Equity value
- USD 22.3bn
Exit at 16.8x EBITDA
81% of EV
- Terminal value, undiscounted
- USD 71.4bn
- Terminal value, discounted
- USD 47.8bn
- Enterprise value
- USD 59.2bn
- Less net debt
- USD 13.8bn
- Equity value
- USD 45.3bn
Spread between methods: 68%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 7.31% | 191.99 | 196.50 | 201.77 | 208.08 | 215.83 |
| 8.31% | 153.50 | 154.86 | 156.32 | 157.92 | 159.68 |
| 9.31% | 127.07 | 127.77 | 128.47 | 129.16 | 129.86 |
| 10.31% | 106.81 | 107.41 | 108.02 | 108.62 | 109.23 |
| 11.31% | 90.16 | 90.69 | 91.22 | 91.75 | 92.28 |
Outlined: this model. Green text: above today's price of 266.42. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 4.2% | 16.3% | +12.1pp |
| EBIT margin | 13.8% | 26.8% | +13.0pp |
| Discount rate | 9.3% | 6.4% | -2.9pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.